Oxford BioMedica PLC (OXBDF)

[marcusl2]

SCIENTIFIC BUSINESS
FRIDAY 8April 2016
SHERWELL LOWER LECTURETHEATRE
SHERWELL BUILDING, PLYMOUTH UNIVERSITY

9:30 a.m.
12) Trovax® And Cyclophosphamide InduceAnti-Tumour Immune ResponsesThat CorrelateWith Prolonged
Survival Of End-Stage Colorectal Cancer Patients
Godkin, A; Pembroke, T; Gallimore, A; Scurr, M
The cytotoxic response to cancer is counteracted by tumour-induced immunosuppression. 54 colorectal cancer patients with
inoperable metastatic disease were randomized to a virus vaccine expressing an oncofetal antigen +/-
cyclophophosphamide to counteract immune regulation. The results of this phase I/II trial demonstrate improved outcome
corresponding to tumour-directed T cell responses.

These were the results from 2007;

August 13, 2007
Oxford BioMedica reported positive results from a phase II trial of TroVax for the treatment of metastatic colorectal cancer. This trial was designed to evaluate the safety and immunogenicity of TroVax when administered with chemotherapy. The trial enrolled 17 subjects who received the vaccine before, during and after the standard chemotherapy regimen FOLFOX. A course of treatment consisted of six vaccinations. Throughout the study, subjects were monitored for an immune response to 5T4. Eleven of the 17 subjects who had completed a course of treatment mounted a strong immune response to 5T4. Of these 11 subjects, six showed significant tumor shrinkage and one no longer had any detectable tumors. The overall median survival was 68 weeks in all 17 vaccinated subjects and 118 weeks in the 11 subjects who received all six vaccinations. Additional phase II and III trials are ongoing at this time.

(without the blood test for those likely to respond)

HTTPS://www.firstwordpharma.com/node/109750?tsid=17